glp-1 long term Research shows drugs are effective but complex The Next Generation of the

Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition

Clinical data demonstrates that gastrointestinal side effects follow a predictable pattern of being most prominent during treatment initiation and dose escalation periods, then declining substantially as the body adapts

Prospective study of fruit and vegetable intake and risk of prostate cancer

J BiochemMolToxicol

Liraglutide Inhibits the Apoptosis of Human Nucleus Pulposus Cells Induced by High Glucose through PI3K/Akt/caspase-3 Signaling Pathway

No need to refrigerate